From the Laboratório de Doenças Auto Imunes, Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Postgraduate Program in Medicine: Medical Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Corporal Michael J. Crescenz VA Medical Center and the University of Pennsylvania, Philadelphia, PA.
J Clin Rheumatol. 2023 Oct 1;29(7):354-362. doi: 10.1097/RHU.0000000000001913. Epub 2022 Oct 27.
Sarcopenia is a condition characterized by decreased muscle strength and muscle mass, which can impact physical function. Sarcopenia develops as a consequence of age-related decline (primary sarcopenia) and has a major impact on physical, social, and emotional well-being. In addition, patients with rheumatic diseases may suffer from sarcopenia independently of aging (secondary sarcopenia). Exercise, pharmacological treatments, and nutritional supplementation are some of the strategies used for the management of sarcopenia in the general population. The aim of this review is to summarize the evidence around the prevalence and impact of sarcopenia in patients with rheumatic diseases.
From our review, we can state that sarcopenia is a common and prevalent condition among the rheumatic diseases. Furthermore, the impacts of sarcopenia are not well-appreciated, and the implementation of treatment strategies has not been widespread. Strategies such as exercise and some pharmacological treatments are effective in improving physical and functional impairment related to these conditions.
New pharmacological treatments are being actively studied and may contribute in the future to the management of sarcopenia.
肌少症是一种以肌肉力量和肌肉质量下降为特征的病症,可能会影响身体机能。肌少症是衰老导致的(原发性肌少症),会对身体、社交和情感健康产生重大影响。此外,患有风湿病的患者可能会出现与年龄无关的肌少症(继发性肌少症)。运动、药物治疗和营养补充是用于治疗普通人群肌少症的一些策略。本综述旨在总结风湿病患者肌少症的患病率和影响的相关证据。
从我们的综述中可以看出,肌少症是风湿性疾病中常见且普遍的病症。此外,肌少症的影响尚未得到充分认识,治疗策略的实施也尚未普及。运动和一些药物治疗等策略可有效改善与这些疾病相关的身体和功能障碍。
新的药物治疗方法正在积极研究中,未来可能有助于肌少症的治疗。